ShakeKumarMD Profile Banner
Abhishek (
Abhishek ("Shake") Kumar, MD MAS

@ShakeKumarMD

Followers
750
Following
7K
Media
136
Statuses
2K

Radiation Oncology Chief Resident @DukeRadOnc | @ARRO_org Executive Committee Vice-Chair

Durham, NC
Joined November 2009
Don't wanna be here? Send us removal request.
@ShakeKumarMD
Abhishek ("Shake") Kumar, MD MAS
2 days
RT @DukeRadOnc: We celebrated Dr. Christopher Willett's two decades of leadership as chair yesterday! We are so grateful for his service, v….
0
3
0
@ShakeKumarMD
Abhishek ("Shake") Kumar, MD MAS
13 days
RT @EPotterMD: I’m sharing an actual recent peer-to-peer call that shows what physicians and patients face when trying to get a surgery app….
0
2K
0
@ShakeKumarMD
Abhishek ("Shake") Kumar, MD MAS
29 days
RT @chr_huang: New year new PGY2s!! 💙 Let's be awesome educators and promote a supportive work environment. We all have the same goals: gre….
0
4
0
@ShakeKumarMD
Abhishek ("Shake") Kumar, MD MAS
30 days
RT @ElliotServaisMD: AIM-HIGH trial published in Lancet.Molecular high-risk stage IA-IIA NSCLC as determined by 14-gene assay with improved….
0
48
0
@ShakeKumarMD
Abhishek ("Shake") Kumar, MD MAS
1 month
RT @DukeRadOnc: Duke #RadOnc is so proud of our graduating residents. Thank you to Drs. Acklin-Wehnert, Gooding, Kumar and Leng for their c….
0
2
0
@ShakeKumarMD
Abhishek ("Shake") Kumar, MD MAS
1 month
RT @jonas_willmann: ❓ESTRO & EORTC proposed a classification to standardize reirradiation. But does it predict outcomes or toxicity?. 🫁☢️ W….
0
15
0
@ShakeKumarMD
Abhishek ("Shake") Kumar, MD MAS
1 month
RT @SuyogCancer: 🌍📚 Calling the global oncology community!.We've launched a WhatsApp Academic Group to share:.🔹 Key trial data.🔹 Conference….
0
17
0
@ShakeKumarMD
Abhishek ("Shake") Kumar, MD MAS
1 month
RT @NicholasZaorsky: My 2025 ASTRO GU #radonc spring refresher presentation (+ hidden slides) is available online.#….
0
43
0
@ShakeKumarMD
Abhishek ("Shake") Kumar, MD MAS
1 month
RT @DrewMoghanaki: From my perspective, this UPMC phase II study for H&N cancers is a landmark randomized clinical trial, even though it en….
0
7
0
@ShakeKumarMD
Abhishek ("Shake") Kumar, MD MAS
1 month
RT @VedangMurthy: During residency, when modems crackled and PubMed barely loaded, I relied on Sem in Rad Oncol for the latest info. Contr….
0
12
0
@ShakeKumarMD
Abhishek ("Shake") Kumar, MD MAS
1 month
RT @ARRO_org: #PGY5 ASTRO Membership Discount! 💸 Join before 12/31 to be eligible and see full details of the discount and benefits on AS….
0
3
0
@ShakeKumarMD
Abhishek ("Shake") Kumar, MD MAS
2 months
RT @MikkaelSekeres: Announcing the first EVER @JCO_ASCO Art of Oncology Narrative Medicine Contest! 🎉✍️🎗️🩺🎉.We're looking for essays that e….
Tweet card summary image
ascopubs.org
0
32
0
@ShakeKumarMD
Abhishek ("Shake") Kumar, MD MAS
2 months
RT @DrAndrewLoblaw: I stand corrected! Well done @VedangMurthy . I’m so glad we have the same questions and drive to answer those question….
0
2
0
@ShakeKumarMD
Abhishek ("Shake") Kumar, MD MAS
2 months
RT @CJTsaiMDPhD: @DrewMoghanaki @_ShankarSiva @TROGfightcancer This is great and much needed. Congrats on getting this through and funded!.
0
1
0
@ShakeKumarMD
Abhishek ("Shake") Kumar, MD MAS
2 months
RT @Erman_Akkus: Organ preservation after total neoadjuvant therapy for locally advanced rectal cancer (CAO/ARO/AIO-16): an open-label, mul….
Tweet card summary image
thelancet.com
Upfront chemoradiotherapy and three cycles of consolidation FOLFOX result in a high rate of clinical complete response with an acceptable toxicity profile. Total neoadjuvant therapy combined with a...
0
43
0
@ShakeKumarMD
Abhishek ("Shake") Kumar, MD MAS
2 months
RT @Sushilberiwal: Finally one positive data on breast cancer for oligoprogression. Focused only on HR positive breast cancer unlike previo….
0
6
0